Targets › SLC5A5
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2027.
Sodium:iodide symporter that mediates the transport of iodide into the thyroid gland. Can also mediate the transport of chlorate, thiocynate, nitrate and selenocynate. (UniProt, Q92911)
Open in Phaseline: the race on SLC5A5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Combination radiotherapy and radiopharmaceutical therapy (CXRPT): external beam Targeted radiotherapy combining external beam radiation and radioactive iodine-131 (RAI/13 | SLC5A5 | Phase 1 | Recurrent Thyroid Cancer | Dec 2027 |
Recurrent Thyroid Cancer (1)
–
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.